Home/Biosimilar Atlas/Companies/Enzene Biosciences

Enzene Biosciences

Biosimilar developer, India. 6 development products across 6 molecules: adalimumab, bevacizumab, denosumab, pertuzumab, ranibizumab, teriparatide.

First approval in the Atlas: Jan 2021, Enzene Biosciences (INN only), teriparatide (CDSCO)
FDAproducts approved0
EMAproducts approved1
MHRAproducts approved0
PMDAproducts approved0
HCproducts approved0
CDSCOproducts approved6
EDEproducts registered0
Connections
6molecules6products2 of 7markets0candidates in trials8companies on the same molecules

About Enzene Biosciences

Enzene, part of Alkem, is one of the newer Indian biosimilar companies and one of the fastest growing. Since 2021 it has received Indian permissions for six molecules: teriparatide, adalimumab, bevacizumab, denosumab, ranibizumab and pertuzumab. Its adalimumab was the first Indian product in the high-concentration form. In 2026 its denosumab reached Europe as Osqay through Theramex, Enzene's first Western approval.

Portfolio by market

MoleculeProductFDAEMAMHRAPMDAHCCDSCOEDEMarkets
AdalimumabEnzene Biosciences adalimumab·····Oct 2022·1/7
BevacizumabEnzene Biosciences bevacizumab·····Feb 2023·1/7
DenosumabOsqay / Enzene denosumab·Jan 2026···Jul 2021·2/7
PertuzumabEnzene Biosciences pertuzumab·····Jun 2025·1/7
RanibizumabEnzene Biosciences ranibizumab·····Aug 2023·1/7
TeriparatideEnzene Biosciences teriparatide·····Jan 2021·1/7

Month shown is the first approval or registration of that product in that market.

In development

ClinicalTrials.gov lists two comparative trials sponsored by Enzene Biosciences for one molecule: denosumab. All of these candidates already have at least one approval in the seven markets.

MoleculeCandidateDeveloper or sponsorReference productPhaseDesignRegistry statusStartedPrimary completionIn the AtlasRegistry record
DenosumabENZ215Enzene BiosciencesProliaPhase 1Comparative PKCompletedJan 2022May 2024Osqay / Enzene denosumabNCT05245669
DenosumabENZ215Enzene BiosciencesProliaPhase 3Comparative efficacyCompletedJul 2022Jul 2024Osqay / Enzene denosumabNCT05405725

Registry data from ClinicalTrials.gov, entered by the sponsors and not verified by any regulator. Status and dates are as posted; sponsors often update them late. Trials registered only on other registries, such as India's CTRI or China's ChiCTR, are not included. Checked 12 Sep 2026.

Companies on the same molecules

Developers whose portfolios overlap most with Enzene Biosciences, by number of shared molecules. Overlap is the clearest sign of who competes with whom for the same tenders and licensing partners.

Intas PharmaceuticalsFive shared molecules: bevacizumab, denosumab, pertuzumab, ranibizumab, teriparatide12 molecules in its portfolioZydus LifesciencesFive shared molecules: adalimumab, bevacizumab, pertuzumab, ranibizumab, teriparatide11 molecules in its portfolioReliance Life SciencesFour shared molecules: adalimumab, bevacizumab, denosumab, ranibizumab14 molecules in its portfolioSamsung BioepisFour shared molecules: adalimumab, bevacizumab, denosumab, ranibizumab10 molecules in its portfolioCelltrionThree shared molecules: adalimumab, bevacizumab, denosumab10 molecules in its portfolioHeteroThree shared molecules: adalimumab, bevacizumab, denosumab5 molecules in its portfolioTevaThree shared molecules: denosumab, ranibizumab, teriparatide5 molecules in its portfolioAlvotechTwo shared molecules: adalimumab, denosumab5 molecules in its portfolio

Chronology

Compare Enzene Biosciences with other developers on the comparison page.

Considering a partner, a licence or a new market for a biosimilar portfolio? EvySaif's regulatory strategy and value dossier work covers the regulatory and market-access side of that decision.

Planning your biosimilar strategy?

EvySaif can help assess your regulatory pathway, clinical evidence requirements and market-entry strategy across India, UAE and other target markets.

Talk to a biosimilar regulatory consultant
Data current to September 2026.